CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 34 enrolled
Drug / intervention
t:slim X2 insulin pump with Control-IQ technology 1.5device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05422053
NCT05422053N/ACompleted
CompareCT.gov

Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)

Tandem Diabetes Care, Inc.·interventional·Posted Jun 16, 2022·Updated Apr 3, 2025

In Brief

A clinical study evaluating t:slim X2 insulin pump with Control-IQ technology 1.5 for Type 1 Diabetes. Completed, enrolled 34 participants across 4 sites.

Detailed Summary

A prospective, single-arm study of 13 weeks of home use of the t:slim X2 insulin pump with Control-IQ technology in individuals with type 1 diabetes who will plan to use at least one basal rate \> 3 units/hr.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedJun 16, 2022
Enrollment StartJun 29, 2022
Primary CompletionJan 6, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.0 years ago

Interventions

t:slim X2 insulin pump with Control-IQ technology 1.5device

t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 CGM.